Pharmaceutically active imidazole derivatives

Thorogood, Peter B.;

The invention relates to a class of imidazoles substituted by cycloalkyl or cycloalkenyl which have pharmacological properties making them useful in medicine, in particular in the prophylaxis and treatment of thrombo-embolic disorders.

The present invention relates to imidazole derivatives and salts thereof, to their synthesis and intermediates therefor, to pharmaceutical formulations containing such compounds and to the use of these compounds in medicine.

Thromboxane A.sub.2 (TXA.sub.2), a potent stimulator of blood platelet aggregation, is produced, in platelets, from the prostaglandin endoperoxides PGG.sub.2 and PGH.sub.2. Prostacyclin (PGI.sub.2), which has potent anti-aggregatory activity, is also produced (in blood vessel walls) from PGG.sub.2 and PGH.sub.2 and it has been suggested that a balance between the production of TXA.sub.2 and PGI.sub.2 is the controlling factor in thrombus formation. It would, in consequence, be desirable in the treatment and prophylaxis of thrombo-embolic disorders to be able to selectively inhibit TXA.sub.2 synthetase, thereby favouring the production of the anti-aggregatory agent PGI.sub.2.

Imidazole and 1-methylimidazole are known to provide some degree of inhibition of the enzymic conversion of the endoperoxides (PGG.sub.2 and PGH.sub.2) to thromboxane A.sub.2 by platelet microsomes (Moncada et al., Prostaglandins, 13/4, 611-618, 1977). Certain 1-n-alkylimidazoles, especially 1-n-dodecylimidazole and its higher homologues have been described as being capable of lowering serum cholesterol levels (U.K. Pat. No. 1 364 312; Biochem. Pharmacol. 24, 1902-1903, 1975).

We have now discovered that TXA.sub.2 synthetase may be inhibited by 1-alkylimidazoles of formula (I) and acid addition salts thereof. The compounds of formula (I) and their salts are hereinafter referred to as the "active compounds".

The compounds of formula (I) are: ##STR1## in which A is a straight or branched, saturated or unsaturated acyclic hydrocarbon radical of from 1 to 3 carbon atoms, n is 0 or 1, and R is a cycloalkyl or cycloalkenyl radical of from 4 to 9, preferably from 5 to 8, carbon atoms and optionally substituted by one, two, three or more alkyl radicals each containing from 1 to 4 carbon atoms, or, when n is 1, A and R together form an alkyl radical of from 4 to 7 carbon atoms or an alkenyl or alkynyl group of from 4 to 9 carbon atoms.

A novel class of compounds within the scope of formula (I) are those of formula (Ia): ##STR2## in which A is a straight or branched, saturated or unsaturated acyclic hydrocarbon radical of from 1 to 3 carbon atoms and R is a cycloalkyl or cycloalkenyl radical of from 4 to 9, preferably from 5 to 8, carbon atoms and optionally substituted by one, two, three or more alkyl radical each containing from 1 to 4 carbon atoms, with the proviso that when A is a methylene radical, R is not unsubstituted cyclohexyl.

In formula (I) and (Ia) examples, cycloalkyl radicals are cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl; cycloalkenyl radicals include cyclohex-3-enyl, cyclopentenyl, and 1,4-cyclohexadienyl; alkenyl radicals include pent-2-enyl and pent-4-enyl.

A valuable class of compounds of formula (I) are those in which n is 1, R is cyclohexyl, cycloheptyl, cyclooctyl, or cycloalkenyl of 6 to 8 carbon atoms, and A is --CH.sub.2 -- or --(CH.sub.2).sub.2 --. Compounds of formula (I) or (Ia) may also be used as acid addition salts thereof, especially as pharmaceutically acceptable ones. Especially preferred compounds include:

1-Cyclooctylmethylimidazole

1-Cyclohex-3-enylmethylimidazole

1-Cyclohexylethylimidazole

and acid addition salts thereof.

Other potent compounds include:

1-Cyclopentylmethylimidazole

1-Cyclooctylvinylimidazole

1-(1-Cyclooctylethyl)imidazole

1-(2-Cyclooctylethyl)imidazole

1-(3-Cyclooctylpropyl)imidazole

1-(Cycloheptylmethyl)imidazole

1-(Cyclohept-2-enylmethyl)imidazole

1-Cyclononylmethylimidazole

1-(4-Methylcyclohexylmethyl)imidazole

1-(Cyclobutylmethyl)imidazole

1-Cycloheptylimidazole

1-Cyclopentylimidazole

1-Cyclohexylmethylimidazole

1-n-Butylimidazole

1-n-Pentylimidazole

1-n-Hexylimidazole

1-Pent-2-enylimidazole

1-Pent-4-enylimidazole

1-(3-Methylbutyl]imidazole

and acid addition salts thereof.

In contrast to imidazole and 1-methylimidazole the compounds of formula (I) are more potent inhibitors of TXA.sub.2 synthetase. Many of the compounds (for example in (I) R is cycloalkyl or cycloalkenyl, n is 1, and A is --CH.sub.2 -- or --(CH.sub.2).sub.2 -- are also more selective in their action in not inhibiting other prostaglandin-generating enzymes such as cyclo-oxygenase. The compounds of formula (I) also do not produce the side-effects found with imidazole upon in vivo administration. The compounds of formula (I) are further capable of inhibiting platelet aggregation in vivo and also are capable of disaggregating platelet clumps. The compounds 1-cyclooctylmethylimidazole, 1-cyclohex-3-enylmethylimidazole and 1-cyclohexylethylimidazole and their salts especially displaying these properties.

Imidazoles of formula (I) and acid addition salts thereof may be made by any method known in the art for the synthesis of compounds of analogous structure. In general these methods comprise linking the imidazole ring to the remainder of the molecule; converting a precursor molecule by elimination of a functional group from the imidazole ring; and formation of the desired compound from a corresponding imidazoline, pyrazole or unsaturated analogue.

A most convenient method of synthesis involves the reaction of imidazole (formula II) or a salt thereof with an alkylating agent of formula (III): ##STR3## wherein R and A are as defined in formula (I) and Z is a leaving group. This reaction is well established in the literature, and the leaving group may be chosen from a variety of substituents but especially halo, preferably chloro or bromo, or from p-toluenesulphonyloxy but other arylsulphonyloxy, alkanesulphonyloxy or aralkylsulphonyloxy radicals may be used. The reaction is preferably performed in the presence of an acid acceptor, for example an alkali metal alkoxide such as sodium methoxide or potassium tertiary butoxide in the presence of the corresponding alkanol. The leaving group Z may itself be formed in situ from the corresponding alkanol (Z=OH) by reaction with a hydrohalogenic acid (e.g. hydrochloric acid or a Lewis acid such as aluminium chloride: see Japanese Patent Kokai No. 131577/77) and the resulting agent of formula (II) reacted directly with imidazole without prior isolation. Alternatively an alkanol (Z=OH) or a derivative thereof (e.g. Z=R--A--O--) may be reacted directly with imidazole (II) by heating in the presence of a dehydrating agent such as phosphoric acid, or a phosphate (see Japanese Patent Publication No. 5 1105 060), sulphuric acid or sulphates (see Japanese Patent Publication No. 5 1105 061).

Among precursor molecules which may be converted to a compound of formula (I) or an acid addition salt thereof, are substituted imidazole derivatives of formula (IV) or addition salts thereof ##STR4## wherein A and R are as defined in formula (I), and Q.sup.1, Q.sup.2 and Q.sup.3 are the same or different, at least one being a radical capable of removal by for example reduction or oxidation, the other being a radical having the same function or is hydrogen. Q.sup.1, Q.sup.2 and Q.sup.3 may be selected from thio (--SH), alkylthio (-Salkyl wherein alkyl has 1 to 4 carbon atoms) or halo preferably chloro or bromo. The reaction conditions are chosen according to the nature of the radicals Q.sup.1, Q.sup.2 and Q.sup.3. Desulphurisation may be performed by oxidative or reductive procedures using for example nitric acid or Raney nickel; and reductive dehalogenation by the use of zinc and acetic acid or Raney nickel or other reagents known in the literature.

Another class of precursors include mono- or dicarboxyimidazoles or derivatives thereof of formula (VI): ##STR5## wherein A and R are as defined in formula (I), at least one of R.sup.1, R.sup.2 and R.sup.4 is carboxyl or a derivative thereof (for example an ester such as an alkyl ester, an acid halide such as the chloride, or the nitrile) and the other is hydrogen or carboxyl or a derivative as described. The compounds of formula (VI) may be converted into the imidazoles of formula (I) by any suitable decarboxylation conditions which may simply comprise heating the compounds with or without a catalyst such as copper.

The imidazoles of formula (I) may also be made from a compound of formula (VII):

N--A.sup.1 --R.sup.3 (VII)

wherein N is 1-imidazoline, 1-imidazole or 1-pyrazole, A.sup.1 is a straight or branched saturated or unsaturated acyclic hydrocarbon radical, and R.sup.3 is a cycloalkyl or cycloalkenyl radical of from 4 to 9 carbon atoms optionally substituted by alkyl as defined in formula (I), provided that at least one of N, A.sup.1 and R.sup.3 is other than 1imidazole, a saturated acyclic hydrocarbon and an optionally substituted cycloalkyl group respectively as defined in formula (I). Thus an imidazoline (VIII): ##STR6## wherein A and R are defined in formula (I) may be dehydrogenated to the corresponding imidazole in the presence of a catalyst for example by heating to 250.degree. C. in the presence of palladium, nickel or platinum under pressure, or by heating with a dehydrogenating agent such as selenium or copper oxide. The 1-pyrazole compounds (VII) may be treated with ultra-violet irradiation, optionally under an inert atmosphere (e.g. argon) in for example 1,2-dimethoxyethane at room or elevated temperatures (see for example "Ring Transformations of Heterocycles" edited van der Plas, Academic Press, 1973 at page 261). The unsaturated imidazoles of formula (I) (in formula (VIII), A.sup.1 and/or R.sup.3 are unsaturated) may be reduced to the corresponding saturated compounds with a noble metal catalyst, for example platinum or palladium in an alkanol.

The intermediates for use in the above described reactions may also be made by conventional methods known in the art. Thus the 1-pyrazole and 1-imidazoline intermediates (formula (VII) may be prepared by alkylation of pyrazole and imidazoline in an analogous manner to that described above for preparation of the corresponding imidazoles. The intermediates of formula (III) may be made in known manner preferably by halogenation of the corresponding alcohols (formula (III), Z=--OH) where in such compounds R is cycloalkenyl; the alcohol is conveniently prepared by the Prins reaction from the cycloalkene and paraformaldehyde (Bull. Chem. Soc. Japan 46/8, 2512-5, 1973). The substituted imidazole intermediates of formula (IV) may be made in known manner, for example see "Imidazole and its derivatives" Part I, Ed. K. Hofmann, Interscience Publishers Inc. New York, 1973. For example the 2-thioimidazoles of formula (IV) may be made by cyclisation of an acetal of formula (IX): ##STR7## with thiocyanate, wherein R.sup.4 is alkyl.

The pharmaceutically acceptable addition salts of the compounds of formula (I) may be prepared by any method known in the art. In particular they may be prepared by treating the parent imidazole with the appropriate acid.

Examples of the addition salts of the compounds of formula (I) include those salts derived from the following acids: oxalic, hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicyclic, succinic, toluene-p-sulphonic, tartaric, acetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic and benzenesulphonic.

The imidazoles of formula (I) may be used in conjunction with a phosphodiesterase inhibitor, which provides a further, synergistic increase in effect, as it acts against platelet aggregation by a different pathway.

Suitable phosphodiesterase inhibitors for use in potentiating the anti-aggregatory effects of the active compounds include as such or as pharmaceutically acceptable salts:

(a) Xanthine derivatives such as:

Theophylline(3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione), and salts thereof.

3-Isobutyl-1-methyl-xanthine;

Caffeine(3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione) and salts thereof; and

Aminophylline (adduct of Theophylline and 1,2ethanediamine (2:1)).

(b) Isoquinoline derivatives, for example:

Papaverine(1-[(3,4-dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline) and salts thereof; and

6,7-Diethoxy-1-(4,5-diethoxybenzyl)isoquinoline or its salts e.g. its hydrochloride;

(c) Derivatives of pyrimido(5,4-d)-pyrimidine, for example:

Dipyridamole(2,2',2",2"'-(4,8-dipiperidinopyrimido[5,4-d]pyrimidin-2,6-diyl dinitrilo)tetraethanol) and its salts;

2,2',2",2"'-[[4-(1-piperidinyl)pyrimido[5,4-d]pyrimidin-2,6-dily]dinitrilo] tetrakisethanol and its salts; and

2,4,6-tri-4-morpholinylpyrimido[5,4-d]pyrimidine and its salts.

(d) Derivatives of thieno[3,2-d]pyrimidine, for example:

N-[4-(4-morpholinyl)thieno]3,2-d[pyrimidin-2-yl]1,2-ethanediamine.

(e) Derivatives of pyrazolo[3',4':2,3]pyrido[4,5-b] [1,5]benzodiazepin-6-(3H)-one, for example:

3-Ethyl-7,12-dihydro-7,12-dimethylpyrazolo[4',3':5,6]pyrido[4,3-b]-[1,5]ben zodiazepin-6-(3H)-one;

3-Ethyl-7,12-dihydro-9-methoxy-7,12-dimethylpyrazolo[3',4':2,3]pyrido[4,5-b ] ]1,5]benzodiazepin-6-(3H)-one; and

10-Chloro-3-ethyl-7,12-dimethyl-7,12-dihydropyrazolo[4',3':5,6]pyrido[4,3-b ] [1,5]benzodiazepin-6-(3H)-one.

(f) Derivatives of 1H- or 2H-pyrazolo[3,4-b]-pyridne, for example:

4-(Butylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester;

4-(Butylamino)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid ethyl ester;

4-Chloro-1-ethyl-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-acetonitrile;

1-Ethyl-4-(isopropylidenehydrazino)-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-c arboxylic acid ethyl ester or its salts such as its hydrochloride hemihydrate; and

2-Methyl-6-phenyl-4-(1-piperidinyl)-2H-pyrazolo[3,4-b]pyridine or its salts e.g. its hydrochloride.

(g) Derivatives of 5H-furo-[3,4-e]pyrazolo[3,4-b]pyridine-5-one, for example:

4-(Butylamino)-1-ethyl-1,7-dihydro-7-hydroxy-5H-furo-[3,4-e]pyrazolo[3,4-b] pyridine-5-one; and

(h) Derivatives of 1(2H)-naphthalenone, for example:

2[(Dimethylamino)methyl]-3,4-dihydro-7-methoxy-1(2H)-naphthalenone or its salts e.g. its 1:1 hydrochloride.

The active compounds are particularly useful in the treatment and/or prophylaxis of thrombo-embolic disorders in mammals, including man. It is to be understood that the term "thrombo-embolic disorders" includes those disorders whose etiology is associated with platelet aggregation.

The active compounds are useful wherever it is desired to inhibit platelet aggregation and/or to reduce the adhesive character of platelets, and consequently to treat or prevent the formation of thrombi in mammals, including man. For example, the compounds are useful in the treatment and prevention of myocardial infarcts cerebro-vascular thrombosis and ischaemic peripheral vascular disease; to treat and prevent post-operative thrombosis; and to promote patency of vascular grafts following surgery.

The active compounds are also useful as an addition to blood, blood products, blood substitutes, and other fluids which are used in artificial extra-corporeal circulation and perfusion of isolated body portions, e.g., limbs and organs, whether attached to the original body, detached and being preserved or prepared for transplant, or attached to a new body. It may also be used in laboratory animals, e.g. cats, dogs, rabbits, monkeys and rats, for these purposes in order to develop new methods and techniques for organ and limb transplants.

The active compounds also exhibit some vasodilatory action on blood vessels and therefore have a utility as anti-hypertensives for the treatment of high blood pressure in mammals, including man.

The amount of active compound required for therapeutic or prophylactic effect will vary with the route of administration, and the nature of the condition under treatment. In general a suitable dose for a mammal, including man, of active compound will lie in the range of 0.1 to 300 mg per kg body weight, particularly from 0.5 to 10 mg per kg body weight, for example 2 mg per kg. A suitable single oral dose for an adult human lies within the range of 50 to 600 mg, for example 150 mg given say three times a day.

While it is possible for the active compounds to be administered as the raw chemical it is preferable to present them as a pharmaceutical formulation. The formulations, both for veterinary and for human medical use, of the present invention comprise an active compound as above defined, together with one or more acceptable carriers therefor and optionally other therapeutic ingredients. The carrier(s) must be `acceptable` in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Unit doses of a formulation may contain between 60 mg and 1.5 g of an active compound.

The formulations include those suitable for oral, rectal, vaginal or parenteral (including subcutaneous, intramuscular and intravenous) administration. Preferred formulations include tablets, capsules and injectable suspensions or solutions.

The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound (in the form of the base or a pharmaceutically acceptable acid addition salt) with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active compound with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired formulation.

It will be appreciated from the foregoing that the present invention provides the following features:

(a) Imidazole of formula (I) or a pharmaceutically acceptable acid addition salt thereof as an active agent for the treatment of a thromboembolic disorder in a mammal or mammalian tissue, including man or human tissue.

(b) Methods of preparing the imidazoles of formula (I) and acid addition salts thereof.

(c) Pharmaceutical formulations contain the imidazoles of formula (I) or as pharmaceutically acceptable acid addition salts thereof and a pharmaceutically acceptable carrier therefor.

(d) Method of preparing a pharmaceutical formulation according to (c).

(e) A method for the treatment or prophylaxis of a thrombo-embolic disorder in a mammal or mammalian tissue, including man or human tissue, comprising administering an active compound.

(f) Novel imidazoles of formula (I) in which n is 1 and A and R together form an alkenyl radical of from 5 to 9 carbon atoms.

(g) Novel imidazoles of formula (I) in which n is 0 (zero) and R is a cycloalkyl or cycloalkenyl group of from 5 to 9 carbon atoms, optionally substituted by one, two, three or more alkyl radicals each containing from 1 to 4 carbon atoms, preferably with the provisor that R is not unsubstituted cyclohexyl, or with the alternative proviso that R is not substituted or unsubstituted cyclohexyl.

The following Examples are provided by way of an illustration of the present invention and should in no way be construed as constituting a limitation thereof. All temperatures are given in degrees Celcius.

EXAMPLE 1

1-Cyclo-octylmethylimidazole

Cyclooctane methyl bromide (5.5 g, 0.027 mole) was added dropwise to a refluxing solution of imidazole (2.0 g, 0.03 mole) in a solution of sodium (0.7 g, 0.03 mole) in absolute ethanol (50 ml). After addition the mixture was refluxed for a further 15 hours.

The solid material was filtered off and the filtrate was concentrated under vacuum. Residue taken up in 2 N hydrochloric acid (100 ml) and washed with ether (25 ml). The aqueous layer was basified by the addition of 10 N aqueous sodium hydroxide solution and then extracted with chloroform (3.times.50 ml). Combined extracts dried over anhydrous magnesium sulphate and chloroform removed under vacuum. Residual oil purified on a silica gel column eluted with ethyl acetate/methanol (9:1). Product distilled under vacuum. B.p. 120.degree.-122.degree. C./0.2 mmHg.

EXAMPLE 2

Preparation of 1-(cyclopentylmethyl)imidazole

A solution of sodium ethoxide was made by dissolving sodium (2.3 g, 0.1 mole) in absolute ethanol (100 ml). Imidazole (6.8 g, 0.1 mole) was then added. The mixture was heated under reflux and cyclopentylmethylbromide (16.3 g, 0.1 mole) was added dropwise. The reaction mixture was allowed to reflux for a further 16 hours after addition. The mixture was then left to cool.

The solid material was then filtered off and the filtrate evaporated down under vacuum. The residue was taken up in 2 N HCl (150 ml) and washed with ether (50 ml). The solution was basified with excess 10 N NaOH and the product extracted with chloroform (3.times.50 ml). Combined extracts were dried over anhydrous MgSO.sub.4 and chloroform removed under vacuum to give yellowish oil.

The crude product was purified on a silica gel column eluted with EtOAc/MeOH (9:1). The product fractions were combined and evaporated down under vacuum to leave 1.9 g of slightly yellowish oil. This was distilled under vacuum. B.pt. 68.degree.-69.degree. C./0.125 mmHg. Yield 0.95 g.

EXAMPLE 3

Preparation of 1-(3-cyclopentylpropyl)imidazole

A solution of sodium ethoxide was prepared by dissolving sodium (0.34 g, 0.0148 mole) in absolute ethanol (30 ml). Imidazole (1.0 g) was then added. The mixture was heated under reflux and 3-cyclopentylpropyl bromide (2.94 g, 0.0153 mole) was added dropwise. The reaction mixture was allowed to reflux for a further 20 hours after addition. The mixture was then allowed to cool.

The solid material was filtered off and the filtrate evaporated down under vacuum. Residue taken up in 2 N HCl (50 ml) and washed with ether (25 ml). The solution was basified with excess 10 N NaOH and the product extracted with chloroform (3.times.25 ml). Combined extracts were dried over anhydrous MgSO.sub.4 and chloroform removed under vacuum to give 2.1 g golden-yellow oil.

The crude product was purified on a silica gel column eluted with EtOAc/MeOH (9:1). The product fractions were combined and evaporated down under vacuum to 1.25 g of slightly yellowish oil. This was distilled under vacuum. B.pt. 89.degree.-90.degree. C./0.1 mmHg. Yield 0.78 g.

EXAMPLE 4

Preparation of 1-(cycloheptylmethyl)imidazole

    ______________________________________
    Potassium t-butoxide (3.1 g, 0.0277 mole)
    Imidazole            (1.90 g, 0.0279 mole)
    Cycloheptylmethyl bromide
                         (5.3 g, 0.02775 mole)
    Dry N-butanol        (50 ml)
    Dry nitrogen
    ______________________________________

• Electrical sensing writing pen Fuel injection system for engine
• Hybrid piston pin Closed loop fuel control method
• Coal binder compositions and methods Camera shake detection apparatus
• Dowel drill fixture Crankshaft-forming apparatus and method
• Advanced heat integrated rectifier system Cable support bracket assembly
• Process for production of ceftiofur Reverse osmosis electrodialysis combined means
• Purification process Food press
• Fast, erectable, easily transportable structures Butterfly type control valve
• Scanning optical rangefinder Method of mixing viscous fluids
• Athletic training glove Floral container
• Anellated .beta.-carbolines Dual post harvesting head
• Storage and merchandising container Self-service terminal
• Vehicle steering system Back-lighting arrangement for illuminated signs
• Backpack Fishing pole holder
• Silver recovery Injectable mesna solutions
• Enhanced subscriber IP alerting LSI package board
• User-interface for a projection device Tire rim holder
• Lightweight impact resistant helmet system Magneto caloric system
• Plastic clip Directionally controllable fishing lure
• Pesticidal formulations Device for dispensing liquids
• IDE interface adapter Analgesic heterocyclic compounds
• Signal recognition system Fastening unit with nail anchorage
• Immunological methods for diagnosing neurocysticercosis Storable bed assembly
• Oil and gas field chemicals Surface marking device and method
• Radical generating system Therapeutic use of tin mesoporphyrin
• Pressure release device Chemical vapor deposition of titanium
• Polarized electromagnet relay Animal collar
• Injection mold for optical discs Electric strike
• Strip casting apparatus Photo display arrangement
• Small library horseshoe architecture Fuel efficiency display
• Self-propelled snowplow vehicle Fluid coking and gasification process
• Amplitude modulated telephone carrier systems Grain for construction material
• Valve disabling mechanism Automatic indexing and transferring apparatus
• Network switch with arbitration sytem Production of corrugated cardboard
• Production of polyurethane foams Electrical receptacle
• Twist beam suspension Apparatus for imaging the anatomy

Cycloheptylmethyl bromide (5.3 g, 0.02775 mole) was added dropwise to a mixture of potassium t-butoxide (3.1 g, 0.0277 mole) and imidazole (1.9 g, 0.0279 mole) in dry n-butanol, the temperature of the oil bath being 120.degree. C. After the addition (about 20 minutes) the temperature of the reaction mixture was raised to boiling, and stirring, and heating under reflux was continued for 7 hours, when examination by t.l.c. showed that no further reaction had taken place.

The insoluble material was filtered off, and the butanol was removed under reduced pressure to afford a pale yellow oil.

The oil was dissolved in 2 N-HCl (100 ml) and the acid solution washed with ether (100 ml). The acid solution was then basified with 10 M NaOH, and the resulting oil extracted with chloroform (3.times.50 ml). The chloroform extracts were combined and dried.

Evaporation of the chloroform solution afforded 2.0 g pale yellow oil. T.l.c. shows imidazole still present. The oil was applied to a silica column and eluted with EtOAc/MeOH 9:1.

Evaporation of the fractions containing pure 1-(cycloheptylmethyl)imidazole afforded 1.3 g pale yellow oil. Distillation of the oil under reduced pressure afforded a colourless oil. B.p. 92.degree.-94.degree. C./0.1 mmHg. Yield 0.63 g.

EXAMPLE 5

(a) Preparation of 2-cyclooctenyl methanol (using the prins reaction NCHIDA Etal. Bull Chem. Soc. Jap. 46, 2512 (1973))

To a stirred suspension of paraformaldehyde (24 g; 0.64 mol) in 98% formic acid (100 cm.sup.3) was added dropwise with stirring cyclooctene (69 g; 0.64 mol). After addition the mixture was stirred under reflux for 2 hours. After addition of water (100 cm.sup.3) and ether (50 cm.sup.3) the mixture was separated. The ether layer was washed with saturated NaHCO.sub.3 solution (5.times.50 cm.sup.3), water (2.times.50 ml) and dried over anhydrous MgSO.sub.4. The ether was removed under vacuum and the residue distilled. Six fractions and residue were obtained.

    ______________________________________
    Fraction 1-Bp. <80.degree./24 mmHg
                              Combined via TLC
    Fraction 2-Bp. 80.degree.-110.degree./24 mmHg
                              Yield 21.5 g
    Fraction 3-Bp. 110.degree.-130.degree./0.5 mmHg
    Fraction 4-Bp. 110.degree.-116.degree./0.3 mmHg
                              Combined via TLC
    Fraction 5-Bp. 116.degree.-130.degree./0.3 mmHg
                              Yield 45.3 g
    Fraction 6-Bp. 130.degree.-170.degree./0.3 mmHg
    ______________________________________

    ______________________________________
    Fraction  8-Bp. <128.degree./23 mmHg
                                 Combined
    Fraction  9-Bp. 128-130.degree./23 mmHg
                                 via TLC
    Fraction 10-Bp. 130-132.degree./23 mmHg
                                 Yield 6.7 g
    ______________________________________

                  TABLE A
    ______________________________________
    Compound             ED.sub.50
    (Reference Compound) .mu.g/ml Selectivity
    ______________________________________
    (Imidazole)          .gtoreq.500
                                  0 to +
    (1-Methylimidazole)  .gtoreq.200
                                  ++
    1-Cycloheptylimidazole
                         .about.6 ++
    1-Cyclopentylmethylimidazole
                         .about.5 +++
    1-Cyclohexylethylimidazole
                          4       +++
    1-Cyclooctylmethylimidazole
                          4       +++
    1-Cyclohex-3-enylmethylimidazole
                         .about.5 +++
    1-Cyclobutylmethylimidazole
                          50      +++
    1-Cyclopentylimidazole
                          125     +++
    ______________________________________

    ______________________________________
    1-Cyclooctylmethylimidazole (as a salt)
                              150 mg
    Starch                     25 mg
    Polyvinylpyrrolidone       2 mg
    Magnesium stearate         3 mg
    ______________________________________

    ______________________________________
    The Imidazole Compound (as a salt)
                              150 mg
    Lactose                   100 mg
    Starch                     30 mg
    Polyvinylpyrrolidone       2 mg
    Magnesium stearate         3 mg
    ______________________________________

    ______________________________________
    The Imidazole Compound (as a salt)
                              100 mg
    Sodium starch glycolate    10 mg
    Polyvinylpyrrolidone       2 mg
    Magnesium stearate         3 mg
    ______________________________________

    ______________________________________
    The Imidazole Compound (as a salt)
                              150 mg
    Starch                     25 mg
    Pregelled starch           5 mg
    Magnesium stearate         3 mg
    ______________________________________

    ______________________________________
    Imidazole compound of formula (I)
                            15.0 g
    Lactic Acid B.P.        q.s. to pH 3.0
    Water for Injections for B.P.
                            to 100.0 ml
    ______________________________________

    ______________________________________
    Imidazole compound of formula (I)
                            15.0 g
    Citric Acid B.P.        q.s. to pH 3.0
    Chlorocresol            0.1 g
    Water for Injections to 100.0 ml
    ______________________________________

                  TABLE I
    ______________________________________
    Active compound          ED.sub.50
    (Reference compound)     .mu.g/ml
    ______________________________________
    (Imidazole)              .gtoreq.500
    (1-methylimidazole)      .gtoreq.200
    1-n-Butylimidazole       10
    1-n-Pentylimidazole      7
    1-n-Hexylimidazole       10
    1-Pent-2-enylimidazole   10
    1-Pent-4-enylimidazole   23
    1-(3-Methylbutyl)imidazole
                             20
    1-Cyclohexylmethylimidazole
                             2.5
    ______________________________________